Asterias Biotherapeutics has initiated patient enrolment for its Phase 1/2a clinical trial of AST-OPC1 stem cells for treating newly injured people with complete cervical spinal cord injury.
“The Phase 1 study generated a strong package of data regarding the safety of AST-OPC1,” said Donald Peck Leslie, M.D., medical director of Shepherd Center and principal investigator for this study site. “With the Phase 1/2a clinical trial, we are excited to begin testing AST-OPC1 at the doses and in the population where it has the maximum potential to bring benefit to patients.”